High Expression of Anti-apoptotic Protein Bcl-2 is a Good Prognostic Factor in Colorectal Cancer: Result of a Meta-analysis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2017 Aug 9

PMID 28785155

Citations 20

Authors

Qi Huang

Shu Li

Pu Cheng

Mei Deng

Xin He

Zhen Wang

Cheng-Hui Yang

Xiao-Ying Zhao

Jian Huang

Affiliations

Soon will be listed here.

Abstract

Aim: To systematically evaluate the prognostic-predictive capability of Bcl-2 in colorectal cancer (CRC).

Methods: A systematic literature search was conducted using PubMed, Web of Science and EMBASE databases. Any eligible study must meet the following criteria: (1) bcl-2 expression was evaluated in human CRC tissues by immunohistochemistry; (2) assessment of the relationships between bcl-2 expression and overall survival (OS), disease free survival (DFS), recurrent free survival (RFS) or clinic-pathological characteristics of CRC was included; (3) sufficient information was provided to estimate the hazard ratio (HR) or odds ratio and their 95% confidence intervals (CIs); and (4) the study was published in English. The impact of Bcl-2 expression on survival of CRC patients were evaluated through this meta-analysis.

Results: A total of 40 eligible articles involving 7658 patients were enrolled in our final analysis. We drew the conclusion that Bcl-2 high expression was significantly correlated with favorable OS (pooled HR = 0.69, 95%CI: 0.55-0.87, = 0.002) and better DFS/RFS (pooled HR = 0.65, 95%CI: 0.50-0.85, = 0.001). Additionally, the subgroup analysis suggested that Bcl-2 overexpression was significantly associated with prognosis (OS) especially in patients came from Europe and America but not Asian and patients who did not receive any adjuvant therapy before surgery. Finally, our present results indicated that expression of bcl-2 protein was associated with high differentiation grade and A/B Ducks' stage.

Conclusion: Bcl-2 high expression was significantly correlated with favorable OS and better DFS/RFS. Hence, we propose that Bcl-2 may be a valuable prognostic-predictive marker in CRC.

Citing Articles

Anastasis and Other Apoptosis-Related Prosurvival Pathways Call for a Paradigm Shift in Oncology: Significance of Deintensification in Treating Solid Tumors.

Mirzayans R Int J Mol Sci. 2025; 26(5).

PMID: 40076508 PMC: 11900100. DOI: 10.3390/ijms26051881.

Bcl-2 and galectin-3 expression is associated with recurrence of ameloblastoma.

Mahdavi N, Saffar H, Derakhshan S, Saffar H, Heidari N Dent Res J (Isfahan). 2025; 21():69.

PMID: 39802810 PMC: 11722749. DOI: 10.4103/drj.drj_706_23.

MicroRNA‑24 alleviates colorectal cancer progression via a rs28382740 single nucleotide polymorphism in the long noncoding region of X‑linked inhibitor of apoptosis protein.

Tian Y, Huang C, Liu C, Yang S, Hung C, Lin K Oncol Lett. 2024; 28(6):591.

PMID: 39417038 PMC: 11481099. DOI: 10.3892/ol.2024.14724.

Changing the Landscape of Solid Tumor Therapy from Apoptosis-Promoting to Apoptosis-Inhibiting Strategies.

Mirzayans R Curr Issues Mol Biol. 2024; 46(6):5379-5396.

PMID: 38920994 PMC: 11202608. DOI: 10.3390/cimb46060322.

Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection.

Kamel F, Eltarhoni K, Nisar P, Soloviev M Cancers (Basel). 2022; 14(8).

PMID: 35454792 PMC: 9029324. DOI: 10.3390/cancers14081889.

References

Garrity M, Burgart L, Mahoney M, Windschitl H, Salim M, Wiesenfeld M . Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol. 2004; 22(9):1572-82. DOI: 10.1200/JCO.2004.10.042. View

Lustosa S, Logullo A, Artigiani R, Saad S, Goldenberg A, Matos D . Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras. 2005; 20(5):353-7. DOI: 10.1590/s0102-86502005000500003. View

Meleth S, Chatla C, Katkoori V, Anderson B, Hardin J, Jhala N . Comparison of predicted probabilities of proportional hazards regression and linear discriminant analysis methods using a colorectal cancer molecular biomarker database. Cancer Inform. 2009; 3:115-22. PMC: 2675853. View

Yang J, Liu X, Bhalla K, Kim C, Ibrado A, Cai J . Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997; 275(5303):1129-32. DOI: 10.1126/science.275.5303.1129. View

Meterissian S, Kontogiannea M, Linjawi A, Halwani F, Jamison B, Edwardes M . Bcl-2 is a useful prognostic marker in Dukes' B colon cancer. Ann Surg Oncol. 2001; 8(6):533-7. DOI: 10.1007/s10434-001-0533-3. View

Ishijima N, Miki C, Ishida T, Kinoshita T, Suzuki H . The immunohistochemical expression of BCL-2 oncoprotein in colorectal adenocarcinoma. Surg Today. 1999; 29(7):682-4. DOI: 10.1007/BF02483002. View

Zlobec I, Terracciano L, Tornillo L, Gunthert U, Vuong T, Jass J . Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut. 2008; 57(10):1413-9. DOI: 10.1136/gut.2007.141192. View

Xu F, Xu J, Lou Z, Di M, Wang F, Hu H . Micropapillary component in colorectal carcinoma is associated with lymph node metastasis in T1 and T2 Stages and decreased survival time in TNM stages I and II. Am J Surg Pathol. 2009; 33(9):1287-92. DOI: 10.1097/PAS.0b013e3181a5387b. View

Tollenaar R, van Krieken J, van Slooten H, Bruinvels D, Nelemans K, van den Broek L . Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer. 1998; 77(11):1842-7. PMC: 2150312. DOI: 10.1038/bjc.1998.306. View

10.

Buglioni S, DAgnano I, Cosimelli M, Vasselli S, DAngelo C, Tedesco M . Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer. 1999; 84(6):545-52. DOI: 10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2. View

11.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

12.

Tsamandas A, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatsoris T . Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome. In Vivo. 2007; 21(1):113-8. View

13.

Czabotar P, Lessene G, Strasser A, Adams J . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013; 15(1):49-63. DOI: 10.1038/nrm3722. View

14.

Handoll H . Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil. 2006; 87(6):875. DOI: 10.1016/j.apmr.2006.04.006. View

15.

Chatla C, Jhala N, Katkoori V, Alexander D, Meleth S, Grizzle W . Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomark. 2006; 1(4-5):241-50. PMC: 2667690. DOI: 10.3233/cbm-2005-14-507. View

16.

Zavrides H, Zizi-Sermpetzoglou A, Elemenoglou I, Papatheofanis I, Peros G, Athanasas G . Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance. Pol J Pathol. 2007; 57(3):149-59. View

17.

Paradiso A, Simone G, Lena M, Leone B, Vallejo C, Lacava J . Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer. 2001; 84(5):651-8. PMC: 2363782. DOI: 10.1054/bjoc.2000.1658. View

18.

Lindner A, Salvucci M, Morgan C, Monsefi N, Resler A, Cremona M . BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut. 2016; 66(12):2141-2148. DOI: 10.1136/gutjnl-2016-312287. View

19.

Baretton G, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K . Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer. 1996; 77(2):255-64. DOI: 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO;2-L. View

20.

Fucini C, Messerini L, Saieva C, Orzalesi L, Carroni V, Bartolini N . Apoptotic proteins as prognostic markers and indicators of radiochemosensitivity in stage II/III rectal cancers. Colorectal Dis. 2011; 14(2):e64-71. DOI: 10.1111/j.1463-1318.2011.02763.x. View